Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Development of nonreducible technetium-99m(III) cations as myocardial perfusion imaging agents: initial experience in humans

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:5606128
A series of 15 nonreducible technetium-99m (III) complexes of formula tr-(/sup 99m/TcL(Y)2)+ has been prepared by a general synthetic route based on reductive addition of Y to the technetium-99m (/sup 99m/Tc) intermediate (/sup 99m/TcL(O))+. In these complexes, selected for potential use as myocardial imaging agents, L represents one of the two tetradentate Schiff base ligands N,N'-ethylenebis(acetylacetone iminato), (en), or N,N'-propylene-1,2-bis(acetylacetone iminato), (pn), while Y represents a monodentate phosphine, phosphite or isonitrile ligand as exemplified by P(CH3)3, P(OCH3)3 and CN-C(CH3)3. Of these 15 complexes, several with octanol/saline partition coefficients in the range 0.04-20 exhibit significant myocardial uptake in rats and dogs. Of these, none exhibit detectable myocardial washout, providing strong support for the hypothesis that myocardial washout occurs only for those /sup 99m/Tc(III) cations that undergo in vivo reduction to the neutral /sup 99m/Tc(II) form. Evaluation of the prototypical complex tr-(/sup 99m/Tc(en)(P(CH3)3)2)+ in seven normal volunteers and patients establishes that it is only a mediocre myocardial imaging agent in man.
Research Organization:
Univ. of Cincinnati, OH
OSTI ID:
5606128
Journal Information:
J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 28:12; ISSN JNMEA
Country of Publication:
United States
Language:
English